Pharmacokinetics of the analogs at C3 and C5 of m-nifedipine in beagle dogs

Biopharmaceutics and Drug Disposition

Volumn 29, Issue 9, 2008, Pages 485-494

  Yang, Zhi Fu ^a   Zhou, Si Yuan ^b   Yang, Tie Hong ^b   Liu, Xin You ^b   Mei, Qi Bing ^b  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^b FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

1,4 DIHYDRO 2,6 DIMETHYL 4 (3 NITROPHENYL) 3,5 PYRIDINEDICARBOXYLIC ACID METHYL PENTYL ESTER; MN 9201; MN 9203; NIFEDIPINE; NIFEDIPINE DERIVATIVE; UNCLASSIFIED DRUG;

ANALYSIS OF VARIANCE; ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG STRUCTURE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MALE; MAXIMUM PLASMA CONCENTRATION; MEAN RESIDENCE TIME; NONHUMAN; PLASMA CONCENTRATION-TIME CURVE;

ANIMALS; AREA UNDER CURVE; DOGS; MALE; MOLECULAR STRUCTURE; NIFEDIPINE; REPRODUCIBILITY OF RESULTS;

EID: 59849109199     PISSN: 01422782     EISSN: 1099081X     Source Type: Journal    
DOI: 10.1002/bdd.618     Document Type: Article

References (21)

1. Roden DM. Antiarrhythmic drugs. In Goodman and Gilman's: The Pharmacological Basis of Therapeutics, Hardman JG, Limbird LE, Goodman GA (eds). McGraw-Hill: TX, 2001; 933-967.
2. Van Zwieten PA, Pfaffendorf M. Pharmacology of the dihydropyridine calcium antagonists: relationship between lipophilicity and pharmacodynamic responses. J Hypertens Suppl 1993; 11: S3-S8.
3. Borchard U. Calcium antagonists in comparison: view of the pharmacologist. J Cardiovasc Pharmacol 1994; 24: S85-S91.
4. Mei QB, Shang P, Zhao DH, Zhou GQ. Comparison of photosensitivity of five dihydropyridines. Chin Pharm J 1998; 33: 291-294.
5. Yang ZF, Zhou SY, Yang TH,Mei QB. Pharmacokinetics of m-nifedipine in Beagle dogs. Acta Pharm Sin 2004; 39: 609-612.
6. Pietta P, Rava A, Biondi P. High-performance liquid chromatography of nifedipine, its metabolites and photochemical degradation products. J Chromatogr 1981; 210: 516-521.
7. Alvarez L, Naranjo LJ, Nũnez V, Squella JA. Electrochemical study of nisoldipine: analytical application in pharmaceutical forms and photodegradation. J Pharm Biomed Anal 1998; 16: 853-862.
8. Alvarez L, Sturm J, Squella JA, Nũnez V. Hydrolytic degradation of nitrendipine and nisoldipine. J Pharm Biomed Anal 2002; 28: 887-895.
9. Ragno G, Cione E, Garofalo A, et al. Design and monitoring of photostability systems for amlodipine dosage forms. Int J Pharm 2003; 265: 125-132.
10. Marinkovic VD, Danica D, Agbaba D, Karljikovic-Rajic K, Comor J, Zivanov-Stakic D. UV derivative spectrophotometric study of the photochemical degradation of nisoldipine. Farmaco 2000; 55: 128-133.
11. Marinkovic VD, Agbaba D, Karljikovic-Rajic K, Vladimirov S, Nedeljkovic JM. Photochemical degradation of solidstate nisoldipine monitored by HPLC. J Pharm Biomed Anal 2003; 32: 929-935.
12. Schleifer KJ. Stereoselective characterization of the 1,4-dihydropyridine binding site at L-type calcium channels in the resting state and the opened/inactivated state. J Med Chem 1999; 42: 2204-2211.
13. Wikel JH, Bemis KG, Kurz K, et al. Comparative QSAR studies of two series of 1,4-dihydropyridines as slow calcium channel blockers. Drug Des Discov 1994; 11: 1-14.
14. Coronado R, Ahern CA, Sheridan DC, Cheng W, Carbonneau L, Bhattacharya D. Functional equivalence of dihydropyridine receptor alpha1S and beta1a subunits in triggering excitation-contraction coupling in skeletal muscle. Biol Res 2004; 37: 565-575.
15. Gupta SP, Veerman A, Bagaria P. Quantitative structure-activity relationship studies on some series of calcium channel blockers. Mol Divers 2004; 8: 357-363.
16. Nguyen JT, Velazquez CA, Knaus EE. Hantzsch 1,4-dihydropyridines containing a diazen-1-ium-1,2-diolate nitric oxide donor moiety to study calcium channel antagonist structure-activity relationships and nitric oxide release. Bioorg Med Chem 2005; 13: 1725-1738.
17. Dagnino L, Li-Kwong-Ken MC, Wolowyk MW, Wynn H, Triggle CR, Knaus EE. Synthesis and calcium channel antagonist activity of dialkyl 1,4-dihydro-2,6-dimethyl-4-(pyridinyl)-3,5-pyridinedicarboxylates. J Med Chem 1986; 29: 2524-2529.
18. Berntsson P, Johansson E, Westerlund C. Felodipine analogs: structure-activity relationships. J Cardiovasc Pharmacol 1987; 10: S60-S65.
19. Mohri K, Uesawa Y, Sagawa K. Effects of long-term grapefruit juice ingestion on nifedipine pharmacokinetics: induction of rat hepatic P-450 by grapefruit juice. Drug Metab Dispos 2000; 28: 482-486.
20. Konno Y, Degawa M. Gene activations of CYP2B1 and CYP3A1 by dihydropyridine calcium channel antagonists in the rat liver: the structure-activity relationship. Biol Pharm Bull 2004; 27: 903-905.
21. Katoh M, Nakajima M, Yamazaki H, Yokoi T. Inhibitory potencies of 1,4-dihydropyridine calcium antagonists to P-glycoprotein-mediated transport: comparison with the effects on CYP3A4. Pharm Res 2000; 17: 1189-1197.